These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27249715)

  • 41. Editorial: New Therapeutic Approaches for the Treatment of Glioblastoma.
    Festuccia C; Gravina GL
    Curr Cancer Drug Targets; 2017; 17(3):200-202. PubMed ID: 28322151
    [No Abstract]   [Full Text] [Related]  

  • 42. Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities.
    Kuramitsu S; Yamamichi A; Ohka F; Motomura K; Hara M; Natsume A
    Immunotherapy; 2016 Dec; 8(12):1393-1404. PubMed ID: 28000534
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current challenges in designing GBM trials for immunotherapy.
    Weathers SP; Gilbert MR
    J Neurooncol; 2015 Jul; 123(3):331-7. PubMed ID: 25577401
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunotherapy in glioblastoma: emerging options in precision medicine.
    Hodges TR; Ferguson SD; Heimberger AB
    CNS Oncol; 2016 Jul; 5(3):175-86. PubMed ID: 27225028
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Advances in Immunotherapy for Glioblastoma Multiforme.
    Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
    J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Developing immunotherapeutic strategies to target brain tumors.
    Lieberman NA; Moyes KW; Crane CA
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):775-88. PubMed ID: 27253692
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The progress of immunotherapy for glioblastoma.
    Zhou Q; Wang Y; Ma W
    Hum Vaccin Immunother; 2015; 11(11):2654-8. PubMed ID: 26308501
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Emerging therapies for glioblastoma.
    Thomas AA; Brennan CW; DeAngelis LM; Omuro AM
    JAMA Neurol; 2014 Nov; 71(11):1437-44. PubMed ID: 25244650
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular advances of brain tumors in radiation oncology.
    Noda SE; El-Jawahri A; Patel D; Lautenschlaeger T; Siedow M; Chakravarti A
    Semin Radiat Oncol; 2009 Jul; 19(3):171-8. PubMed ID: 19464632
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of regulatory T cells and microglia in glioblastoma-associated immunosuppression.
    See AP; Parker JJ; Waziri A
    J Neurooncol; 2015 Jul; 123(3):405-12. PubMed ID: 26123363
    [TBL] [Abstract][Full Text] [Related]  

  • 51. T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints.
    Mirzaei R; Sarkar S; Yong VW
    Trends Immunol; 2017 Feb; 38(2):104-115. PubMed ID: 27964820
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells.
    Authier A; Farrand KJ; Broadley KW; Ancelet LR; Hunn MK; Stone S; McConnell MJ; Hermans IF
    Int J Cancer; 2015 Jun; 136(11):2566-78. PubMed ID: 25363661
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The future of therapy for glioblastoma.
    Kornblith PK; Welch WC; Bradley MK
    Surg Neurol; 1993 Jun; 39(6):538-43. PubMed ID: 8390727
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combining immunotherapy with radiation for the treatment of glioblastoma.
    Chow KK; Hara W; Lim M; Li G
    J Neurooncol; 2015 Jul; 123(3):459-64. PubMed ID: 25877468
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?
    Lester A; Rapkins R; Nixdorf S; Khasraw M; McDonald K
    Clin Transl Oncol; 2017 Mar; 19(3):273-278. PubMed ID: 27655368
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glioblastoma stem cells and stem cell-targeting immunotherapies.
    Esparza R; Azad TD; Feroze AH; Mitra SS; Cheshier SH
    J Neurooncol; 2015 Jul; 123(3):449-57. PubMed ID: 25682090
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutics and Research Related to Glioblastoma: Advancements and Future Targets.
    Chavda V; Patel V; Yadav D; Shah J; Patel S; Jin JO
    Curr Drug Metab; 2020; 21(3):186-198. PubMed ID: 32268863
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel approaches and mechanisms of immunotherapy for glioblastoma.
    Hegde M; Bielamowicz KJ; Ahmed N
    Discov Med; 2014 Mar; 17(93):145-54. PubMed ID: 24641957
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential Expression and Clinical Significance of Transforming Growth Factor-Beta Isoforms in GBM Tumors.
    Roy LO; Poirier MB; Fortin D
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29642484
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biomarkers for glioma immunotherapy: the next generation.
    Sims JS; Ung TH; Neira JA; Canoll P; Bruce JN
    J Neurooncol; 2015 Jul; 123(3):359-72. PubMed ID: 25724916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.